Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity

Provided By PR Newswire

Last update: Jul 15, 2025

PRINCETON, N.J., July 15, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced strong preclinical results for PL7737, an oral selective melanocortin-4 receptor (MC4R) agonist, showing effectiveness in rodent models of obesity.